JP2019513394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513394A5 JP2019513394A5 JP2018553980A JP2018553980A JP2019513394A5 JP 2019513394 A5 JP2019513394 A5 JP 2019513394A5 JP 2018553980 A JP2018553980 A JP 2018553980A JP 2018553980 A JP2018553980 A JP 2018553980A JP 2019513394 A5 JP2019513394 A5 JP 2019513394A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- nucleic acid
- domain
- isolated
- callar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 83
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 82
- 108010054218 Factor VIII Proteins 0.000 claims description 44
- 102000001690 Factor VIII Human genes 0.000 claims description 44
- 229960000301 factor viii Drugs 0.000 claims description 44
- 239000012634 fragment Substances 0.000 claims description 29
- 230000000961 alloantigen Effects 0.000 claims description 27
- 108020003175 receptors Proteins 0.000 claims description 25
- 102000005962 receptors Human genes 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 24
- 108010043610 KIR Receptors Proteins 0.000 claims description 23
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 17
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 17
- 230000003834 intracellular effect Effects 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 15
- 102100026735 Coagulation factor VIII Human genes 0.000 claims description 14
- 208000031220 Hemophilia Diseases 0.000 claims description 14
- 208000009292 Hemophilia A Diseases 0.000 claims description 14
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000004068 intracellular signaling Effects 0.000 claims description 10
- 230000001086 cytosolic effect Effects 0.000 claims description 9
- 230000000139 costimulatory effect Effects 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 102000006306 Antigen Receptors Human genes 0.000 claims description 4
- 108010083359 Antigen Receptors Proteins 0.000 claims description 4
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 claims description 4
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 claims description 4
- 230000031146 intracellular signal transduction Effects 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 2
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 230000019491 signal transduction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096329A JP2022133308A (ja) | 2016-04-15 | 2022-06-15 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
| JP2024107077A JP2024138334A (ja) | 2016-04-15 | 2024-07-03 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322937P | 2016-04-15 | 2016-04-15 | |
| US62/322,937 | 2016-04-15 | ||
| PCT/US2017/027754 WO2017181101A1 (en) | 2016-04-15 | 2017-04-14 | Compositions and methods of chimeric alloantigen receptor t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096329A Division JP2022133308A (ja) | 2016-04-15 | 2022-06-15 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513394A JP2019513394A (ja) | 2019-05-30 |
| JP2019513394A5 true JP2019513394A5 (enExample) | 2020-05-28 |
Family
ID=60042268
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553980A Pending JP2019513394A (ja) | 2016-04-15 | 2017-04-14 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
| JP2022096329A Pending JP2022133308A (ja) | 2016-04-15 | 2022-06-15 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
| JP2024107077A Pending JP2024138334A (ja) | 2016-04-15 | 2024-07-03 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096329A Pending JP2022133308A (ja) | 2016-04-15 | 2022-06-15 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
| JP2024107077A Pending JP2024138334A (ja) | 2016-04-15 | 2024-07-03 | キメラアロ抗原受容体ｔ細胞の組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190153064A1 (enExample) |
| EP (1) | EP3443076A4 (enExample) |
| JP (3) | JP2019513394A (enExample) |
| KR (1) | KR20190003550A (enExample) |
| CN (1) | CN109328230A (enExample) |
| AU (2) | AU2017248817A1 (enExample) |
| CA (1) | CA3020599A1 (enExample) |
| MX (1) | MX2018012539A (enExample) |
| RU (1) | RU2018140056A (enExample) |
| WO (1) | WO2017181101A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019157496A1 (en) * | 2018-02-12 | 2019-08-15 | University Of Florida Researchfoundation, Inc. | Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a |
| CA3110926A1 (en) * | 2018-08-28 | 2020-03-05 | Pharos Vaccine Inc. | Improved lentiviral vector |
| EP3845564A4 (en) * | 2018-08-28 | 2022-05-18 | Immunotech Biopharm Co., Ltd. | ENHANCED THERAPEUTIC T LYMPHOCYTE |
| CN110903399B (zh) * | 2018-09-17 | 2022-02-01 | 台湾中国医药大学附设医院 | 嵌合抗原受体、其核酸、表达质体、细胞、用途及组合物 |
| US20220184129A1 (en) * | 2019-04-12 | 2022-06-16 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
| WO2020231999A1 (en) * | 2019-05-13 | 2020-11-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells |
| WO2021091945A1 (en) * | 2019-11-05 | 2021-05-14 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy of multiple myeloma |
| EP4150058A4 (en) * | 2020-05-13 | 2024-06-19 | Nanjing Legend Biotech Co., Ltd. | COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENIC CELLS USING MONKEY ICP47 AND VARIANTS THEREOF |
| CN113646433B (zh) * | 2020-07-16 | 2022-10-11 | 苏州博腾生物制药有限公司 | 靶向抗TNF-α抗体的组合物和方法 |
| US20230270782A1 (en) * | 2020-09-03 | 2023-08-31 | Porton Advanced Solutions Ltd. | Compositions and methods to target anti-rh antibody |
| WO2022083590A1 (zh) * | 2020-10-19 | 2022-04-28 | 南京卡提医学科技有限公司 | 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法 |
| CN114369168B (zh) * | 2020-10-19 | 2024-08-30 | 南京卡提医学科技有限公司 | 包含dap12和共刺激信号分子信号域的嵌合受体及其使用方法 |
| CN116103239A (zh) * | 2021-11-11 | 2023-05-12 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| US20250352580A1 (en) * | 2022-11-04 | 2025-11-20 | The Children's Hospital Of Philadelphia | Compositions and methods for b cell directed immunotherapies for anti-aav neutralizing alloantibodies |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US466A (en) | 1837-11-20 | Jordan l | ||
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| ES2653570T3 (es) | 2004-05-27 | 2018-02-07 | The Trustees Of The University Of Pennsylvania | Células presentadoras de antígeno artificiales novedosas y usos de las mismas |
| EP3219723B1 (en) * | 2009-08-27 | 2021-10-06 | Novo Nordisk A/S | Targeting tissue factor to activated platelets |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| BR112015000657B1 (pt) * | 2012-07-13 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | Uso de uma célula geneticamente modificada para expressar um car |
| US9790282B2 (en) * | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| EP4008725A1 (en) * | 2014-05-02 | 2022-06-08 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| JP2017521046A (ja) * | 2014-05-08 | 2017-08-03 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | 有害な免疫応答を処置するための寛容原性タンパク質療法としてのＢ細胞標的化抗原ＩｇＧ融合物の使用 |
| EP3384013A4 (en) * | 2015-12-04 | 2019-07-10 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | ANTIGEN-SPECIFIC T CELLS FOR INDUCING IMMUNOTOLERANCE |
-
2017
- 2017-04-14 KR KR1020187032117A patent/KR20190003550A/ko not_active Ceased
- 2017-04-14 US US16/093,539 patent/US20190153064A1/en not_active Abandoned
- 2017-04-14 CA CA3020599A patent/CA3020599A1/en active Pending
- 2017-04-14 AU AU2017248817A patent/AU2017248817A1/en not_active Abandoned
- 2017-04-14 WO PCT/US2017/027754 patent/WO2017181101A1/en not_active Ceased
- 2017-04-14 CN CN201780036162.2A patent/CN109328230A/zh active Pending
- 2017-04-14 RU RU2018140056A patent/RU2018140056A/ru unknown
- 2017-04-14 MX MX2018012539A patent/MX2018012539A/es unknown
- 2017-04-14 JP JP2018553980A patent/JP2019513394A/ja active Pending
- 2017-04-14 EP EP17783306.8A patent/EP3443076A4/en active Pending
-
2021
- 2021-08-23 US US17/409,354 patent/US20220220188A1/en not_active Abandoned
-
2022
- 2022-06-15 JP JP2022096329A patent/JP2022133308A/ja active Pending
-
2023
- 2023-09-01 AU AU2023222993A patent/AU2023222993A1/en active Pending
-
2024
- 2024-07-03 JP JP2024107077A patent/JP2024138334A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513394A5 (enExample) | ||
| JP2018508219A5 (enExample) | ||
| JP6664528B2 (ja) | Ｃｌｄ１８ａ２標的免疫エフェクター細胞及びその調製方法と使用 | |
| RU2018140056A (ru) | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена | |
| JP2020511136A5 (enExample) | ||
| JP2024062986A (ja) | 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞 | |
| TWI775768B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| EP3914611B1 (en) | Receptors providing targeted costimulation for adoptive cell therapy | |
| JP2020114264A5 (enExample) | ||
| KR102235202B1 (ko) | T 세포 수용체 베타 불변 영역에 대한 항원 결합 도메인을 갖는 키메라 항원 수용체(car) | |
| JP2025032089A (ja) | 腫瘍微小環境を標的とするキメラ抗原受容体 | |
| JP2024156654A (ja) | 新規操作ｔ細胞受容体およびそれを使用した免疫療法 | |
| JP2023036657A (ja) | 修飾されたｔ細胞及びその使用方法 | |
| JP2017537919A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| CN108137670A (zh) | Ny-eso-1特异性tcr及其使用方法 | |
| KR20170101206A (ko) | 조작된 감마 델타 t 세포 | |
| RU2017133637A (ru) | Иммуномодулирующие слитые белки и пути их применения | |
| JP2019530431A5 (enExample) | ||
| JP2015513920A5 (enExample) | ||
| EP3568466A1 (en) | Targeted t cells with cytotoxicity toward immunosuppressive cells | |
| JP7483746B2 (ja) | Ｍａｇｅａ１特異的ｔ細胞受容体およびその使用 | |
| JP2025107358A (ja) | 細胞 | |
| CA3173527A1 (en) | Methods for generating engineered memory-like nk cells and compositions thereof | |
| US20220064256A1 (en) | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |